Loading...
FGB Scalpel (MT4) — review, price and free alternatives
MT4 expert advisor$699 on MQL5by Vitalii Zakharuk
FGB Scalpel is a MetaTrader 4 expert advisor by Vitalii Zakharuk, sold on the MQL5 Market for $699. It can't be downloaded here: buy it, or try its free demo, on its MQL5 page. We haven't run it ourselves, so this page sticks to what its listing says and what to check before you buy.
FGB Scalpel — key facts
- Platform
- MetaTrader 4 (MT4)
- Product type
- Expert advisor
- Developer
- Vitalii Zakharuk
- Price
- $699
- Listing
- MQL5 Market (mql5.com)
- FxRobotEasy verification status
- FxRobotEasy has not traded FGB Scalpel on a live account and publishes no broker-verified performance record for it.
Last updated
What the developer says
The expert system FGB Scalpel works with a deposit of $ 100!
Before you buy FGB Scalpel
What the developer claims
- The classic scalping trading method.
- It is also worth noting that at an acceptable level of spread, the bot goes through any historical period on any currency pair.
- The key is the spread, it works with the default settings, it is possible to work with a spread of up to 10.
Quoted from the listing. We have not tested these claims.
What to check first
- A live track record. Ask for an MQL5 signal on a real account, ideally three months or longer. Back-tests and screenshots are not a track record.
- The free demo first. The MQL5 Market lets you run a free demo of a paid MT4 expert advisor in the Strategy Tester before you buy.
- Risk controls. Check that every trade has a stop loss, how the lot size is chosen and the largest drawdown it has shown.
- Broker conditions. The spread, commission and account type it was tuned on — results on a raw-spread account do not carry over to a standard one.
- Updates and support. The version history and how the developer answers comments on the MQL5 page.
Editorial notes on FGB Scalpel
Compiled from its public MQL5 listing. FxRobotEasy has not traded FGB Scalpel; what these notes say about how it works comes from that listing.
Overview
FGB Scalpel by Vitalii Zakharuk represents a comprehensive automated trading solution for MT4 traders. What sets FGB Scalpel apart is its balanced approach to trade execution and capital preservation.
Risk notes
FGB Scalpel implements a moderate risk profile with configurable parameters for different trading styles. The system uses stop losses on all positions and employs dynamic position sizing based on account equity. Recommended minimum account size ensures proper risk distribution.
Listed strengths
- MT4 platform compatibility
- Developed by experienced Vitalii Zakharuk
- Includes risk management features
Worth checking
- Requires adequate account capital
- Not suitable for all market conditions
- Needs proper configuration
Setup
Installing FGB Scalpel on MT4 requires copying the EA file to your platform's Experts directory. After restart, attach to appropriate charts and configure risk parameters. Always backtest with historical data before live deployment.
Free to try · from FxRobotEasy
Looking for a scalping robot you can try free?
Our robots at work. Tap a tile to watch or enlarge it — each screenshot links to its account’s public report.
Scalperology AIby FxRobotEasy
Our multi-pair AI scalper — majors, gold and crypto
- Get the installer on a Windows PCNo sign-up to download. On a phone, send yourself the link.
- Run it and sign in inside the appGoogle, Telegram or e-mail — about 10 minutes in all.
- Pick Scalperology AIIt starts on a free demo account: virtual money, every trade visible.
FxRobotEasy on Telegram
The team's notes, every day
- What we ship, what breaks and how we fix it
- Scalperology AI in our bot — set up from your phone, run it on a Windows PC
- Questions answered in the bot
FGB Scalpel or Scalperology AI?
| FGB Scalpel | Scalperology AI | |
|---|---|---|
| How you get it | Buy on MQL5 ($699) | Free installer; runs on a demo account first |
| Platform | MT4 | MT5 |
| Public account reports | — | Yes — see the screenshots above |
| Made by | Vitalii Zakharuk | FxRobotEasy |
FGB Scalpel — questions
What is FGB Scalpel?
FGB Scalpel is a MetaTrader 4 Expert Advisor (trading robot) published on the MQL5 Market by Vitalii Zakharuk, priced at $699 USD. As an Expert Advisor it can open and manage positions on its own once it is attached to a chart and algorithmic trading is enabled in the terminal.
Does FGB Scalpel work on MT4 or MT5?
FGB Scalpel runs on MetaTrader 4, not MetaTrader 5. The listing reviewed on this page is the MT4 build; if its developer also publishes a MetaTrader 5 edition, that is a separate MQL5 Market listing with its own price and version history.
How much does FGB Scalpel cost?
FGB Scalpel is a paid product listed at $699 USD on the MQL5 Market, the price recorded when its listing was last checked on 2026-09-23. It is sold and downloaded through the developer's (Vitalii Zakharuk) page on mql5.com; FxRobotEasy neither sells it nor hosts the file.
Is there a verified track record for FGB Scalpel?
FxRobotEasy has not traded FGB Scalpel on a live account, so no independently verified track record for it is published here. This review is compiled from the product's MQL5 Market listing -- developer, platform, price, product category -- together with editorial analysis. Any back-tested or simulated figures shown alongside it are simulations rather than live trading results, and any performance claim you find for FGB Scalpel elsewhere comes from its developer or from a third party.
Similar expert advisors
Scalperology AIFree demo · by FxRobotEasyFree- Fibo Expansion Auto Redraw Trade ManagerMT4 · Bartlomiej Jacek Matwiejczuk$299
- Ferret AIMT4 · Anastasiya Morozova$199
- Fibonacci Of YesterdayMT4 · Thushara Dissanayake$38
- FerrerDCAMT4 · Leonardo Garcia FerrerFree
- Fibonacci Trader EAMT4 · Mohammad Khairy Abdul Ghany$50
Product data from the MQL5 marketplace. Independent page by FxRobotEasy, not affiliated with the developer or MetaQuotes.
Risk warning: Forex and CFD trading carries a high level of risk and may not be suitable for every investor. Past performance is not indicative of future results. Read our risk warning and review methodology.